The results showed that the Erb-B2 receptor tyrosine kinase 3 (ERBB3) and transforming growth factor alpha (TGFA) genes were downregulated, suggesting that quadrigemine I treatment may block the activation of the ErbB signaling pathway, inhibit the growth and proliferation of lymphoma cells, and induce their apoptosis. Here, EGFR is linked to lymphoma.